Maximum Recommended Dose of Dextromethorphan
For adults and children 12 years and older, the maximum dose of dextromethorphan is 20 mL (60 mg) per 24 hours; for children 6 to under 12 years, the maximum is 10 mL (30 mg) per 24 hours; for children 4 to under 6 years, the maximum is 5 mL (15 mg) per 24 hours; and dextromethorphan should not be used in children under 4 years of age 1.
Age-Based Dosing Guidelines
The FDA-approved dosing for dextromethorphan extended-release oral suspension follows a strict age-based schedule 1:
Adults and Children ≥12 Years
- Dose: 10 mL every 12 hours
- Maximum daily dose: 20 mL in 24 hours (equivalent to 60 mg dextromethorphan hydrobromide)
Children 6 to Under 12 Years
- Dose: 5 mL every 12 hours
- Maximum daily dose: 10 mL in 24 hours (equivalent to 30 mg dextromethorphan hydrobromide)
Children 4 to Under 6 Years
- Dose: 2.5 mL every 12 hours
- Maximum daily dose: 5 mL in 24 hours (equivalent to 15 mg dextromethorphan hydrobromide)
Children Under 4 Years
- Do not use
Important Clinical Considerations
Weight-based dosing variability: While FDA labeling uses age-based dosing, research demonstrates this results in substantial variability in actual drug exposure (0.35 to 0.94 mg/kg per dose) 2. Clinical observations suggest medium-dose (0.45 to <0.60 mg/kg) or high-dose (0.60-0.94 mg/kg) dextromethorphan may provide better symptomatic relief than low-dose (<0.45 mg/kg), though adverse events occur more frequently at higher doses 2.
Limited efficacy evidence: Despite widespread use, dextromethorphan's effectiveness for acute cough remains uncertain. One study showed no difference in cough frequency or severity with 30 mg dextromethorphan compared to placebo in adults with upper respiratory infections 3. The American Academy of Pediatrics does not support its routine use in children 2.
Measurement precision: Always use the dosing cup provided with the specific product, as dosing cups are not interchangeable between products 1.
Genetic considerations: Dextromethorphan metabolism varies significantly based on CYP2D6 phenotype. Poor metabolizers have dramatically prolonged half-lives (29.5 hours vs 16.4 hours in extensive metabolizers) and higher parent drug concentrations 4. This genetic variability affects both efficacy and risk of adverse effects, though routine genotyping is not standard practice.
Drug interactions: Quinidine and other CYP2D6 inhibitors significantly suppress dextromethorphan metabolism, elevating plasma concentrations and potentially causing toxicity 4.